![https:||www.sec.gov|Archives|edgar|data|1460702|000149315216012231|logo1.jpg](https://capedge.com/proxy/CORRESP/0001493152-19-011342/image_001.jpg)
Ritter Pharmaceuticals, Inc.
1880 Century Park East, Suite 1000
Los Angeles, CA 90067
(310) 203-1000
July 30, 2019
VIA EDGAR
United States Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Attention: Julia Griffith
| Re: | Ritter Pharmaceuticals, Inc. – Request for Acceleration |
| | Registration Statement on Form S-1 |
| | File No. 333- 232792 |
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Ritter Pharmaceuticals, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333- 232792) (the “Registration Statement”), so that it may become effective at4:30 p.m. Eastern Standard Time on August 1, 2019, or as soon thereafter as practicable.
The Registrant hereby authorizes each of Wendy Grasso, Esq., Aron Izower, Esq. and Michael Sanders, Esq. of Reed Smith LLP, attorneys for the Registrant, to orally modify or withdraw this request for acceleration.
The Registrant requests that it be notified of such effectiveness by a telephone call to Wendy Grasso at (212) 549-0216 or, in her absence, Mr. Izower at (212) 549-0393 or Mr. Sanders at (310) 734-5232.
| RITTER PHARMACEUTICALS, INC. |
| |
| By: | /s/Andrew J. Ritter |
| | Andrew J. Ritter |
| | Chief Executive Officer |